查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1427234

全球抗凝血剂市场规模、份额、成长分析、按药物类别、分销管道 - 2023-2030 年产业预测

Global Anticoagulants Market Size, Share, Growth Analysis, By Drug class(Vitamin K Antagonists (VKAs) and Direct Oral Anticoagulants (DOACs)), By Distribution channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2023-2030
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球抗凝血药物市场规模为285亿美元，预计将从2023年的314.4亿美元增至2031年的688.7亿美元，并预计在预测期内（2024-2031年）持续增长。）复合年增长率为10.30%。

近年来，随着慢性病的流行和不健康的生活习惯导致心血管疾病的增加，全球抗凝血药物市场出现了显着增长。因此，市场上对抗凝剂的需求不断增加。根据世界卫生组织 (WHO) 和 Cureus 医学科学杂誌的数据，心血管疾病位居全球头号死因之一，每年约造成 1790 万人死亡，占全球整体死亡人数的 35%。我是。其中 85% 的死亡是由于心臟病和中风造成的。缺血性心臟疾病(IHD) 已成为全球死亡率的重要原因，影响约 1.26 亿人，约占世界人口的 1.72%。据预测，到 2030 年，IHD 盛行率预计将超过每 10 万人 1,845 人。抗凝血剂透过防止血液凝固，在降低心臟病、中风和其他心血管併发症的风险方面发挥重要作用。除了传统的抗凝血治疗之外，新型口服抗凝血剂（NOAC）也引起了人们的关注。这些新药比Warfarin等传统抗凝血剂具有优势，包括改进的安全性、更简单的给药方案和更少的药物交互作用。医疗保健专业人员和患者越来越多地采用 NOAC，进一步推动了全球抗凝血剂市场的成长。

自上而下和自下而上的方法已用于估计和检验全球抗凝血剂市场的规模，并估计其他各个相关子市场的规模。用于估计市场规模的调查方法包括以下细节：透过二次研究确定市场中的主要企业，并透过初步和二次研究确定每个地区的市场占有率。整个过程包括研究主要企业的年度和财务报告以及广泛的采访，以获得执行长、副总裁、董事和行销负责人等行业领导者的重要见解。所有股份比率和细分均使用二手资讯确定并使用主要资讯检验。所有可能影响本研究涵盖的市场的参数都经过了详细的考虑和研究，透过初步研究检验和分析，以获得最终的定量和定性资料。

全球抗凝血剂市场細項分析

全球抗凝血剂市场按药物类别、分销管道和地区细分。依药物类别分为维生素K拮抗（vkas）和直接口服抗凝血剂（doacs）。根据分销管道，市场分为医院药房、零售药房和网路药房。从区域来看，市场分为北美、欧洲、亚太地区、中东和非洲以及拉丁美洲。

全球抗凝血市场的驱动因素

全球抗凝血剂市场的关键驱动因素之一是全球心血管疾病（包括缺血性心臟疾病（IHD））盛行率的不断上升。心血管疾病每年导致数百万人死亡，增加了对预防心臟病和中风的有效治疗方法的需求。疾病负担的增加导致抗凝血剂的需求增加，推动市场成长。此外，与传统抗凝血剂相比，新型口服抗凝血剂（NOAC）的采用提高了安全性和便利性，进一步刺激了市场扩张。

全球抗凝血药市场的限制因素

全球抗凝血药物市场的一个显着限制是与抗凝血治疗相关的出血併发症的可能性。抗凝血剂在预防血栓方面发挥重要作用，但它们也会增加出血事件的风险，在某些情况下可能危及生命。平衡抗凝血治疗的益处和潜在副作用对医疗专业人员来说是一个挑战。此外，与抗凝血剂相关的高成本阻碍了其可用性，特别是在新兴市场，进一步限制了市场成长。

全球抗凝血药物市场趋势

全球抗凝血药物市场的一个显着趋势是，相对于Warfarin等传统抗凝血疗法，人们越来越青睐直接口服抗凝血药物（DOAC）。 DOAC 具有剂量可预测、药物交互作用较少、减少频繁监测的需要、提高病患依从性等优点。向 DOAC 的转变是由于其便利性和更高的安全性。此外，正在进行的研究和开发旨在扩大 DOAC 的适应症，使其在市场上越来越受欢迎。

目录

  • 执行摘要
  • 调查方法
  • 母市场分析
  • 主要市场考察
    • 技术分析
    • 价格分析
    • 供应链分析
    • 价值链分析
    • 市场生态系统
    • 智慧财产权分析
    • 贸易分析
    • Start-Ups分析
    • 原料分析
    • 创新矩阵
    • 研发线产品分析
    • 总体经济指标
    • 主要投资分析
    • 关键成功因素
    • 竞争程度
  • 市场动态及展望
    • 市场动态
      • 促进因素
      • 机会
      • 抑制因素
      • 任务
    • 监管形势
    • 波特的分析
    • 对未来中断的特殊考虑
  • 全球抗凝血剂市场：依药物类别
    • 市场概况
    • 维生素 K 拮抗剂 (VKA) 和直接口服抗凝血剂 (DOAC)
  • 全球抗凝血剂市场：按分销管道划分
    • 市场概况
    • 医院药房
    • 零售药房
    • 网路药房
  • 全球抗凝血剂市场规模：按地区划分
    • 市场概况
    • 北美洲
      • 美国
      • 加拿大
    • 欧洲
      • 德国
      • 西班牙
      • 法国
      • 英国
      • 其他欧洲国家地区
    • 亚太地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 其他亚太地区
    • 拉丁美洲
      • 巴西
      • 其他拉丁美洲地区
    • 中东和非洲 (MEA)
      • 海湾合作委员会国家
      • 南非
      • 其他中东/非洲地区
  • 竞争形势
    • 前5名企业对比
    • 主要企业市场定位（2021年）
    • 主要市场参与者所采取的策略
    • 关键成功策略
    • 近期市集活动
    • 主要企业市场占有率（2021年）
  • 主要企业简介
    • Pfizer Inc.（US）
    • Bayer AG（Germany）
    • Bristol Myers Squibb Company（US）
    • Johnson & Johnson（US）
    • Boehringer Ingelheim International GmbH（Germany）
    • Sanofi SA（France）
    • Daiichi Sankyo Company, Limited（Japan）
    • Novartis International AG（Switzerland）
    • Eli Lilly and Company（US）
    • AstraZeneca PLC（UK）
    • Merck & Co., Inc.（US）
    • GlaxoSmithKline PLC（UK）
    • Abbott Laboratories（US）
    • Aspen Pharmacare Holdings Limited（South Africa）
    • Otsuka Holdings Co., Ltd.（Japan）
    • Mylan NV（US）
    • Takeda Pharmaceutical Company Limited（Japan）
    • Leo Pharma A/S（Denmark）
    • Portola Pharmaceuticals, Inc.（US）
    • CSL Limited（Australia）
简介目录
Product Code: SQMIG35B2093

Global Anticoagulants Market size was valued at USD 28.50 Billion in 2022 and is expected to grow from USD 31.44 Billion in 2023 to reach USD 68.87 Billion by 2031, at a CAGR of 10.30% during the forecast period (2024-2031).

The global anticoagulants market has experienced substantial growth recently, propelled by the increasing prevalence of chronic diseases and the adoption of unhealthy lifestyles contributing to a rise in cardiovascular diseases. This has led to a heightened demand for anticoagulants in the market. According to the World Health Organization (WHO) and the Cureus Journal of Medical Science, cardiovascular diseases rank among the leading causes of global mortality, accounting for around 17.9 million deaths annually, representing 35% of total global deaths. Within these fatalities, 85% are linked to heart attacks and strokes. Ischemic heart disease (IHD) has emerged as a significant contributor to worldwide mortality, affecting approximately 126 million individuals globally, representing about 1.72% of the global population. Projections suggest that the prevalence of IHD is anticipated to exceed 1,845 per 100,000 individuals by the year 2030. Anticoagulants play a crucial role in preventing blood clotting, thereby reducing the risk of heart attacks, strokes, and other cardiovascular complications. Alongside traditional anticoagulant therapies, novel oral anticoagulants (NOACs) have gained prominence. These newer drugs offer advantages such as improved safety profiles, simplified dosing regimens, and fewer drug interactions compared to traditional anticoagulants like warfarin. The increasing adoption of NOACs by healthcare professionals and patients has further propelled the growth of the global anticoagulants market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anticoagulants Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anticoagulants Market Segmental Analysis

Global Anticoagulants Market is segmented by drug class, distribution channel, and region. Based on drug class, the market can be segmented into vitamin k antagonists (vkas), and direct oral anticoagulants (doacs). Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Anticoagulants Market

One key driver of the global anticoagulants market is the increasing prevalence of cardiovascular diseases, including ischemic heart disease (IHD), worldwide. With millions of deaths each year attributed to cardiovascular diseases, there is a growing need for effective treatments to prevent heart attacks and strokes. This rising disease burden has resulted in a higher demand for anticoagulant medications, driving the growth of the market. Additionally, the adoption of novel oral anticoagulants (NOACs) has further fueled the market expansion, offering improved safety and convenience compared to traditional anticoagulants.

Restraints in the Global Anticoagulants Market

A notable constraint for the global anticoagulants market is the potential for bleeding complications linked to anticoagulant therapy. Although these medications play a crucial role in preventing blood clots, they also elevate the risk of bleeding events, which, in certain instances, can be life-threatening. Balancing the benefits of anticoagulant therapy against the potential adverse effects poses a challenge for healthcare professionals. Moreover, the high cost associated with anticoagulant medications can impede their accessibility, particularly in developing regions, further constraining the growth of the market.

Market Trends of the Global Anticoagulants Market

A notable trend in the global anticoagulants market is the growing preference for direct oral anticoagulants (DOACs) over traditional anticoagulant therapies like warfarin. DOACs present benefits such as predictable dosing, fewer drug interactions, and reduced necessity for frequent monitoring, enhancing patient adherence. The shift towards DOACs is propelled by their convenience and improved safety profiles. Furthermore, ongoing research and development endeavors aim to broaden the scope of indications for DOACs, contributing to their increasing popularity in the market.

Table of Contents

  • Executive Summary
    • Market Overview
    • Wheel of Fortune
  • Research Methodology
    • Information Procurement
    • Secondary & Primary Data Sources
    • Market Size Estimation
    • Market Assumptions & Limitations
  • Parent Market Analysis
    • Market Overview
    • Market Size
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Key Market Insights
    • Technology Analysis
    • Pricing Analysis
    • Supply Chain Analysis
    • Value Chain Analysis
    • Ecosystem of the Market
    • IP Analysis
    • Trade Analysis
    • Startup Analysis
    • Raw Material Analysis
    • Innovation Matrix
    • Pipeline Product Analysis
    • Macroeconomic Indicators
    • Top Investment Analysis
    • Key Success Factor
    • Degree of Competition
  • Market Dynamics & Outlook
    • Market Dynamics
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
    • Regulatory Landscape
    • Porters Analysis
      • Competitive rivalry
      • Threat of Substitute Products
      • Bargaining Power of Buyers
      • Threat of New Entrants
      • Bargaining Power of Suppliers
    • Skyquest Special Insights on Future Disruptions
      • Political Impact
      • Economic Impact
      • Social Impact
      • Technical Impact
      • Environmental Impact
      • Legal Impact
  • Global Anticoagulants Market by Drug class
    • Market Overview
    • Vitamin K Antagonists (VKAs) and Direct Oral Anticoagulants (DOACs)
  • Global Anticoagulants Market by Distribution channel
    • Market Overview
    • Hospital Pharmacies
    • Retail Pharmacies
    • and Online Pharmacies
  • Global Anticoagulants Market Size by Region
    • Market Overview
    • North America
      • USA
      • Canada
    • Europe
      • Germany
      • Spain
      • France
      • UK
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia-Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Middle East & Africa (MEA)
      • GCC Countries
      • South Africa
      • Rest of MEA
  • Competitive Landscape
    • Top 5 Player Comparison
    • Market Positioning of Key Players, 2021
    • Strategies Adopted by Key Market Players
    • Top Winning Strategies
      • By Development
      • By Company
      • By Year
    • Recent Activities in the Market
    • Key Companies Market Share (%), 2021
  • Key Company Profiles
    • Pfizer Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bayer AG (Germany)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Bristol Myers Squibb Company (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Johnson & Johnson (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Boehringer Ingelheim International GmbH (Germany)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Sanofi S.A. (France)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Daiichi Sankyo Company, Limited (Japan)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Novartis International AG (Switzerland)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Eli Lilly and Company (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • AstraZeneca PLC (UK)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Merck & Co., Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • GlaxoSmithKline PLC (UK)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Abbott Laboratories (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Aspen Pharmacare Holdings Limited (South Africa)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Otsuka Holdings Co., Ltd. (Japan)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Mylan N.V. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Takeda Pharmaceutical Company Limited (Japan)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Leo Pharma A/S (Denmark)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • Portola Pharmaceuticals, Inc. (US)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments
    • CSL Limited (Australia)
      • Company Overview
      • Business Segment Overview
      • Financial Updates
      • Key Developments